Covered recipient · General Payments record
MANISH R PATEL
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$16,177.19
171 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,590.00 | 3 |
| Food and Beverage | $3,336.01 | 159 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,251.18 | 9 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANISH R PATEL
NPI 1457408254 · CMS profile ID 66097
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
SARASOTA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457408254?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANISH R PATEL, NPI 1457408254, CMS profile ID 66097. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457408254?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MANISH R PATEL, NPI 1457408254, CMS profile ID 66097. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457408254?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MANISH R PATEL, NPI 1457408254, CMS profile ID 66097, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1457408254?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
171 matching records · $16,177.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 171.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.66 | 09/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944351769 | CMS |
| Incyte Corporation | $26.01 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943029337 | CMS |
| JAZZ PHARMACEUTICALS INC. | $23.91 | 09/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951328543 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.46 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920251253 | CMS |
| Gilead Sciences, Inc. | $19.14 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929595139 | CMS |
| Incyte Corporation | $26.38 | 09/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943029335 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $23.06 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890345483 | CMS |
| Merck Sharp & Dohme LLC | $20.01 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944222159 | CMS |
| Alnylam Pharmaceuticals Inc. | $15.05 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 926071131 | CMS |
| Daiichi Sankyo Inc. | $24.83 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930823627 | CMS |
| Exelixis Inc. | $14.72 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932464349 | CMS |
| GENZYME CORPORATION | $24.64 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938992681 | CMS |
| Amgen Inc. | $14.56 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939318567 | CMS |
| Novartis Pharmaceuticals Corporation | $21.42 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894210723 | CMS |
| Epizyme, Inc., | $19.51 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917610557 | CMS |
| EISAI INC. | $19.24 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908059941 | CMS |
| Adaptive Biotechnologies Corporation | $25.79 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951430391 | CMS |
| TerSera Therapeutics LLC | $18.22 | 08/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965169931 | CMS |
| Lilly USA, LLC | $24.77 | 08/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918137319 | CMS |
| PFIZER INC. | $19.13 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949250439 | CMS |
| EISAI INC. | $13.24 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908059949 | CMS |
| Sobi, Inc | $17.84 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940363473 | CMS |
| Incyte Corporation | $7.85 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943029319 | CMS |
| Merck Sharp & Dohme LLC | $19.68 | 07/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944205657 | CMS |
| Novartis Pharmaceuticals Corporation | $19.52 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894210719 | CMS |
| Seagen Inc. | $15.06 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904121023 | CMS |
| GT Medical Technologies, Inc | $29.11 | 07/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929370019 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.91 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932615135 | CMS |
| Seagen Inc. | $14.59 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904121021 | CMS |
| Acrotech Biopharma LLC | $16.51 | 07/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937455851 | CMS |
| Lilly USA, LLC | $24.18 | 07/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918172057 | CMS |
| Deciphera Pharmaceuticals Inc. | $19.53 | 07/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 953435167 | CMS |
| ARRAY BIOPHARMA INC | $14.87 | 07/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949350539 | CMS |
| EISAI INC. | $22.39 | 07/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908059945 | CMS |
| Novartis Pharmaceuticals Corporation | $7.95 | 07/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894210715 | CMS |
| Seagen Inc. | $17.09 | 07/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904121019 | CMS |
| Boehringer Ingelheim International GmbH | $462.08 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182425 | CMS |
| Boehringer Ingelheim International GmbH | $232.67 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182429 | CMS |
| Boehringer Ingelheim International GmbH | $209.40 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182433 | CMS |
| Boehringer Ingelheim International GmbH | $299.14 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182437 | CMS |
| Boehringer Ingelheim International GmbH | $692.47 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182441 | CMS |
| Boehringer Ingelheim International GmbH | $513.42 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947182445 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.49 | 06/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920237929 | CMS |
| Janssen Biotech, Inc. | $18.46 | 06/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885748343 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $16.41 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942301095 | CMS |
| Lilly USA, LLC | $24.99 | 06/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918147283 | CMS |
| Merck Sharp & Dohme LLC | $18.62 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944176161 | CMS |
| Incyte Corporation | $24.14 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943029307 | CMS |
| Merck Sharp & Dohme LLC | $11.03 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944303353 | CMS |
| Astellas Pharma US Inc | $14.88 | 06/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940203753 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $7,769,064.14 | 2,999 |
| PY2024 | Principal investigator | $3,591,049.61 | 1,017 |
| PY2023 | Principal investigator | $1,986,878.44 | 417 |
| PY2022 | Principal investigator | $2,985,902.81 | 298 |
| PY2021 | Recipient | $7,607.59 | 4 |
| PY2021 | Principal investigator | $3,326,767.53 | 362 |
| PY2020 | Recipient | $2,584.53 | 4 |
| PY2020 | Principal investigator | $4,078,821.62 | 985 |
| PY2019 | Recipient | $5,673.76 | 1 |
| PY2019 | Principal investigator | $5,858,177.05 | 1,184 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
2,999 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | BioNTech SE | $40.00 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018434 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 12/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739075 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,000.00 | 12/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS9051-079 | No dispute reported | 06/30/2026 | 1223377601 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $28,000.00 | 12/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS9051-079 | No dispute reported | 06/30/2026 | 1223377603 |
| Principal investigator 1 | Janssen Research & Development, LLC | $63,177.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 12/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $316.29 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377029 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,523.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377033 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $720.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377057 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,978.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377087 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $98.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $403.00 | 12/23/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175326948 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327935 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329547 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329641 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380568 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380636 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381252 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327852 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329133 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329173 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329561 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,182.50 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226082325 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327263 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 12/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328014 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 12/17/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 12/17/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.20 | 12/17/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634907 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $95.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796895 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,299.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378323 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378371 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380262 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380282 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380284 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380286 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380288 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380290 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380292 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380294 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380302 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380314 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380316 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380318 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380320 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380326 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380346 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380350 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380352 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380358 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380360 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380366 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380368 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380382 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380406 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380438 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380440 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380442 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380448 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380452 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380454 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380460 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380462 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380464 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380466 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380478 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380482 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380484 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380486 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380556 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380562 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380566 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380572 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380578 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380582 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380608 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380620 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380622 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380632 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380650 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380654 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380668 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380674 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380678 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380696 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380700 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380706 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380878 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381066 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381140 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381182 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381248 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381258 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381264 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381266 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381272 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381282 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381284 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381286 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381290 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381292 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381294 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381306 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381308 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381316 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381326 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381332 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381338 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381340 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381352 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381356 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381364 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381368 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381378 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381380 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381386 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381388 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381408 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381442 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381444 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381450 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381452 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381454 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381460 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381462 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381464 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381468 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381480 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381482 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381484 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381490 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381496 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381498 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381556 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381560 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381562 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381586 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381596 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381604 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381620 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381622 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381632 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381634 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381636 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381638 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381654 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381666 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381670 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381674 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381678 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381690 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381702 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $125,410.30 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226081943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,803.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327327 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,709.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328180 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328202 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329364 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,265.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329482 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,803.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329526 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320548 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321168 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321525 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64,104.75 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors | No dispute reported | 06/30/2026 | 1175326722 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586729 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586733 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586738 |
| Principal investigator 1 | Incyte Corporation | $3,625.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586796 |
| Principal investigator 1 | Incyte Corporation | $3,625.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586799 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586904 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586908 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $125.00 | 12/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226081860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323206 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,629.25 | 12/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226081795 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,538.00 | 12/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377025 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,166.00 | 12/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377041 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380356 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381612 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381668 |
| Principal investigator 1 | Incyte Corporation | $2,850.00 | 12/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586930 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226081864 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,335.50 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226082034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634901 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13.53 | 12/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.22 | 12/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377331 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377335 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377341 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377343 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.55 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377387 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $83.40 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 12/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380444 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380480 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380586 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380590 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380600 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380680 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380690 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,601.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381152 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381354 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381600 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381650 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 12/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381696 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,687.50 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,298.80 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328028 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,690.00 | 11/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739071 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 11/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739073 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586828 |
| Principal investigator 1 | Incyte Corporation | $331.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586843 |
| Principal investigator 1 | Incyte Corporation | $325.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586881 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587038 |
| Principal investigator 1 | Incyte Corporation | $203.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587046 |
| Principal investigator 1 | Incyte Corporation | $203.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587048 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587088 |
| Principal investigator 1 | PFIZER INC. | $300.00 | 11/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228727821 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 11/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381336 |
| Principal investigator 1 | Incyte Corporation | $1,038.52 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,803.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328610 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,300.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328829 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380306 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380374 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380456 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,601.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380574 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380634 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380638 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380686 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381178 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381270 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381314 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381342 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381362 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381372 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381432 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381446 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381566 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381574 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381680 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381684 |
| Principal investigator 1 | Incyte Corporation | $89.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586802 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587080 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587083 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586806 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586810 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586877 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586995 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,265.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175326672 |
| Principal investigator 1 | Janssen Research & Development, LLC | $54.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175326800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175326864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $699.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327780 |
| Principal investigator 1 | Janssen Research & Development, LLC | $410.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $193.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328414 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,803.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $410.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $89.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $171.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377027 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $121.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377031 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $360.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377035 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $196.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377037 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377043 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377045 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $601.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377047 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $126.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $48.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377051 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377053 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $88.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377055 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $403.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377061 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $274.28 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377067 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377075 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,446.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,720.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377079 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $163.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377083 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,400.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377085 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377089 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377091 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377093 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $698.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377095 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,978.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377097 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $60.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377103 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $168.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $386.00 | 11/19/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378291 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378303 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378315 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,775.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378319 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378325 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378329 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378341 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378369 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378373 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378375 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378377 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380270 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380272 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380404 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380498 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380596 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380670 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381288 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381318 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381322 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381572 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381592 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586678 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586689 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586694 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586698 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586703 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586708 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586741 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586745 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586749 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586756 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586760 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586764 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586780 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586785 |
| Principal investigator 1 | Incyte Corporation | $3,093.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586814 |
| Principal investigator 1 | Incyte Corporation | $4,543.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586832 |
| Principal investigator 1 | Incyte Corporation | $601.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586835 |
| Principal investigator 1 | Incyte Corporation | $325.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586838 |
| Principal investigator 1 | Incyte Corporation | $331.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586846 |
| Principal investigator 1 | Incyte Corporation | $331.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586850 |
| Principal investigator 1 | Incyte Corporation | $3,074.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586854 |
| Principal investigator 1 | Incyte Corporation | $3,129.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586868 |
| Principal investigator 1 | Incyte Corporation | $3,129.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586872 |
| Principal investigator 1 | Incyte Corporation | $624.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586883 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586887 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586891 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586896 |
| Principal investigator 1 | Incyte Corporation | $2,850.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586901 |
| Principal investigator 1 | Incyte Corporation | $89.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586916 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586943 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586947 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586951 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586955 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586975 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586978 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586987 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587001 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587004 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587009 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587012 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587016 |
| Principal investigator 1 | Incyte Corporation | $341.71 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587020 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587029 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587033 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380348 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380492 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380594 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380604 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380660 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380692 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381686 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586668 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586671 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586675 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586789 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586793 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586817 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586820 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586920 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586922 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586925 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586960 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586965 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586970 |
| Principal investigator 1 | Incyte Corporation | $4,003.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587071 |
| Principal investigator 1 | Incyte Corporation | $4,003.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587076 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,220.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380266 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380276 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380280 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380332 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380334 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380338 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380342 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380354 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380362 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380370 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380378 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380386 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380388 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380408 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380490 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380496 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380558 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380560 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380588 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380612 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380624 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380642 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380658 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380684 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381112 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381172 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381260 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381334 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381344 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381346 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381348 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381350 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381366 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381370 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381396 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381438 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381448 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381456 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381478 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381558 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381570 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381582 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381588 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381642 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381652 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381658 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381662 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328147 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523929 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,253.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796959 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,043.80 | 11/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380400 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380432 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381114 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381278 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381400 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381402 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381608 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381660 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380264 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380298 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380336 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380344 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380472 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380570 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380598 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380652 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380662 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380890 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381276 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381404 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381406 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381440 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381458 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381568 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381624 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 11/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381700 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 11/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586912 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 11/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587023 |
| Principal investigator 1 | Incyte Corporation | $3,012.00 | 11/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327294 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327312 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329473 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329518 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380278 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380308 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380446 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381298 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381320 |
| Principal investigator 1 | Incyte Corporation | $2,850.00 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586713 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,613.46 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors | No dispute reported | 06/30/2026 | 1175327170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328230 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328796 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 11/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377039 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,573.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,476.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377069 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377081 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 11/05/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377099 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $5,266.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652812 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,500.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652817 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,554.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652823 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,554.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652828 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $15,000.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652836 |
| Principal investigator 1 | PFIZER INC. | $22,653.32 | 11/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228738705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 11/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $354.00 | 11/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368403 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $332.00 | 11/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $166.00 | 11/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $177.00 | 11/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377313 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377315 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377319 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377321 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377327 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377329 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377337 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377361 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377365 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377367 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377369 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377373 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377375 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377377 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $109.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377379 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377381 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377385 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377399 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.40 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 11/03/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380644 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $950.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652806 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $203.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652810 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,500.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652820 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $379.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652832 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,370.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $54.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327616 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,988.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,224.10 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328746 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329055 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,803.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329540 |
| Principal investigator 1 | BioNTech SE | $79.18 | 11/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018430 |
| Principal investigator 1 | BioNTech SE | $25.00 | 11/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634899 |
| Principal investigator 1 | BioNTech SE | $40.00 | 10/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018426 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 10/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739069 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 10/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320204 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 10/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 10/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 10/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326437 |
| Principal investigator 1 | BioNTech SE | $40.00 | 10/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378305 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378321 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378337 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378381 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $5,600.00 | 10/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $186.56 | 10/27/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640489 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328056 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328314 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,265.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175329634 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 10/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228741317 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518033 |
| Principal investigator 1 | ABBVIE INC. | $1,630.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518035 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,400.00 | 10/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) | No dispute reported | 06/30/2026 | 1211652802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378283 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378301 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378313 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378335 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378343 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378361 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378367 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 10/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327436 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327452 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327459 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328132 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328482 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,672.30 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327474 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328329 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328959 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 10/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380340 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380372 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380468 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380666 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $107.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $467.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381262 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381280 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381486 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381578 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381594 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $467.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381598 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380722 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $60,343.37 | 10/12/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w | No dispute reported | 06/30/2026 | 1190302243 |
| Principal investigator 1 | Eli Lilly and Company | $55,065.00 | 10/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1187891676 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586681 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586685 |
| Principal investigator 1 | Incyte Corporation | $4,427.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586722 |
| Principal investigator 1 | Incyte Corporation | $4,427.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586725 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586767 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586772 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586776 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586825 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586857 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586860 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586864 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586938 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586982 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240586991 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587051 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587055 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587062 |
| Principal investigator 1 | Incyte Corporation | $3,625.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587065 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587091 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587094 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240587098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,707.00 | 10/06/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $131,516.00 | 10/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378281 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378309 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378311 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378327 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378331 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378363 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378365 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378385 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380268 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380322 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380364 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380380 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380396 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380402 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380450 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380458 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380592 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,253.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381268 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381302 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381358 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381360 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381374 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381382 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381466 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381472 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381492 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 10/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 10/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796909 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.22 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368253 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $468.70 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368255 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.12 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368257 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $227.10 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368405 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.87 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $234.35 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.61 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.44 | 10/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $309.30 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377323 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377325 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $18.25 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377363 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377371 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377403 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377405 |
| Principal investigator 1 | BioNTech SE | $40.00 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018424 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 09/30/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584867 |
| Principal investigator 1 | Incyte Corporation | $3,129.00 | 09/30/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584871 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 09/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,343.00 | 09/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323541 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,640.75 | 09/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors | No dispute reported | 06/30/2026 | 1175327208 |
| Principal investigator 1 | Incyte Corporation | $341.70 | 09/25/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 09/24/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 09/24/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 09/24/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.60 | 09/24/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.68 | 09/24/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,323.00 | 09/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $326.48 | 09/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 09/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,168.00 | 09/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.80 | 09/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640487 |
| Principal investigator 1 | Incyte Corporation | $4,543.00 | 09/24/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584857 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 09/24/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584863 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 09/24/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584882 |
| Principal investigator 1 | PFIZER INC. | $6,300.00 | 09/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228757410 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,900.00 | 09/23/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190305359 |
| Principal investigator 1 | Janssen Research & Development, LLC | $930.60 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,500.00 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175327884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,000.00 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,137.30 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328446 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,946.40 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328514 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,672.30 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,977.90 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,238.60 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,400.00 | 09/17/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377005 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,080.00 | 09/17/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377023 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378221 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378229 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378237 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378253 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379700 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379722 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380258 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327008 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,675.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,124.50 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors | No dispute reported | 06/30/2026 | 1175328556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175328705 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 09/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $199.00 | 09/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 09/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 09/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377007 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,427.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377009 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,815.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377011 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,861.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377013 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,045.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377015 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,443.00 | 09/11/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377017 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584808 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584812 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584816 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584819 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584824 |
| Principal investigator 1 | Incyte Corporation | $3,475.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584828 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584831 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584835 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584838 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584842 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584845 |
| Principal investigator 1 | Incyte Corporation | $4,003.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584850 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584874 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584878 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584887 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584892 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584897 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584901 |
| Principal investigator 1 | Incyte Corporation | $4,003.00 | 09/11/2025 | Non-covered Recipient Entity SARAH CANNON INTEGRATED CANCER SERVICES | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240584905 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,589.30 | 09/11/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | No dispute reported | 06/30/2026 | 1190305357 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $787.50 | 09/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796957 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600.00 | 09/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814639 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,728.70 | 09/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814641 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600.00 | 09/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814643 |
| Principal investigator 1 | Genentech, Inc. | $1,275.00 | 09/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651779 |
| Principal investigator 1 | Genentech, Inc. | $1,045.00 | 09/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651929 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 09/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226082018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379446 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,500.00 | 09/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323489 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 09/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 09/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,300.00 | 09/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379440 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,400.00 | 09/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $468.70 | 09/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368241 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380066 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380112 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380114 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380212 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 09/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institution Llc | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226147763 |
| Principal investigator 1 | ABBVIE INC. | $2,126.25 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 09/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 09/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 09/01/2025 | Non-covered Recipient Entity University Of Minnesota Division Of Hematology Oncology And Transplantation | A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220634881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,567.31 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,048.50 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,235.81 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,526.69 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639500 |
| Principal investigator 1 | Eli Lilly and Company | $33,406.50 | 08/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1187880077 |
| Principal investigator 1 | Eli Lilly and Company | $255,856.81 | 08/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A FIRST-IN-HUMAN, PHASE 1A/1B TRIAL TO ASSESS THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF LY4175408, AN ANTIBODY DRUG CONJUGATE TARGETING PROTEIN TYROSINE KINASE 7-EXPRESSING TUMOR CELLS, IN PARTICIPANTS WITH SELECTED ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1187881178 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 08/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739055 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $422.50 | 08/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | No dispute reported | 06/30/2026 | 1190301687 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.00 | 08/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190301689 |
| Principal investigator 1 | BioNTech SE | $40.00 | 08/29/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018418 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,391.00 | 08/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319851 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,234.60 | 08/27/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814637 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,312.88 | 08/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1226082022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $264.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,601.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $189.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,601.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380172 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380254 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 08/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $757.00 | 08/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 08/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $171.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $66.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,000.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321144 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $214.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321407 |
| Principal investigator 1 | Janssen Research & Development, LLC | $197.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $130.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322105 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $51.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323337 |
| Principal investigator 1 | Janssen Research & Development, LLC | $61.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $449.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $148.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328951 |
| Principal investigator 1 | PFIZER INC. | $6,600.00 | 08/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228761577 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 08/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202505231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380048 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $205,443.37 | 08/19/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190305355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $325.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $230.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $805.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,396.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379432 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379438 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379442 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379444 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379450 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379452 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,396.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379454 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379456 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379458 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379460 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379462 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379464 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,056.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379466 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379468 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379472 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,264.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379478 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $460.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379480 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,264.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379482 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379484 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379486 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $476.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $805.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379490 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379492 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,264.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379496 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379498 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,264.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $136.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $230.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379556 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379558 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379560 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $230.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379566 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379568 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379572 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $195.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379574 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379578 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $345.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379582 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379586 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379588 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379590 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379620 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379622 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379624 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379632 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379638 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379642 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379644 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379650 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379670 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379674 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379680 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379684 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379686 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379690 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379692 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379696 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $408.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $690.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $792.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $136.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $130.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $136.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $230.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $230.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $792.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $518.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $690.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $408.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $130.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379890 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380178 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $272.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $195.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $204.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 08/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380256 |
| Principal investigator 1 | Incyte Corporation | $601.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586591 |
| Principal investigator 1 | Incyte Corporation | $2,850.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319948 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319958 |
| Principal investigator 1 | Janssen Research & Development, LLC | $66.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319974 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320062 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321974 |
| Principal investigator 1 | Janssen Research & Development, LLC | $608.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324359 |
| Principal investigator 1 | Janssen Research & Development, LLC | $81.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,952.36 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324915 |
| Principal investigator 1 | Janssen Research & Development, LLC | $59.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325173 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326414 |
| Principal investigator 1 | BioNTech SE | $15.84 | 08/17/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018420 |
| Principal investigator 1 | BioNTech SE | $25.00 | 08/17/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380230 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586553 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586557 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586561 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586565 |
| Principal investigator 1 | Incyte Corporation | $3,625.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586570 |
| Principal investigator 1 | Incyte Corporation | $3,625.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586574 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586578 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586582 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586586 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586612 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379706 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378223 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378225 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 08/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378271 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,600.00 | 08/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378191 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378195 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378227 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378277 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379448 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379562 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379570 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379592 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379594 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379596 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379598 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379600 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,101.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379604 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379612 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379634 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379636 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379652 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379654 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379658 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379660 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379662 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379666 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379668 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379678 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379878 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380248 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380252 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380260 |
| Principal investigator 1 | Genentech, Inc. | $2,427.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651724 |
| Principal investigator 1 | Genentech, Inc. | $7,247.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651732 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651743 |
| Principal investigator 1 | Genentech, Inc. | $847.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652032 |
| Principal investigator 1 | Genentech, Inc. | $21,741.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652047 |
| Principal investigator 1 | Genentech, Inc. | $8,318.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652055 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652179 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652236 |
| Principal investigator 1 | Genentech, Inc. | $7,247.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652336 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586339 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586342 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586355 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586358 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586362 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586366 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586371 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586375 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586379 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586382 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586387 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586395 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586398 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586402 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586406 |
| Principal investigator 1 | Incyte Corporation | $2,502.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586411 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586417 |
| Principal investigator 1 | Incyte Corporation | $6,469.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586421 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586424 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586433 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586437 |
| Principal investigator 1 | Incyte Corporation | $7,209.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586441 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586445 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586449 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586454 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586634 |
| Principal investigator 1 | Incyte Corporation | $4,433.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586643 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586647 |
| Principal investigator 1 | Incyte Corporation | $3,251.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586653 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586660 |
| Principal investigator 1 | Incyte Corporation | $5,242.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $63,409.00 | 08/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,800.00 | 08/07/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377003 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $215.00 | 08/07/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377019 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,400.00 | 08/07/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377021 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586459 |
| Principal investigator 1 | Incyte Corporation | $5,700.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586463 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586467 |
| Principal investigator 1 | Incyte Corporation | $14,500.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586471 |
| Principal investigator 1 | Incyte Corporation | $1,049.52 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586475 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586480 |
| Principal investigator 1 | Incyte Corporation | $13,000.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586595 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586599 |
| Principal investigator 1 | Incyte Corporation | $2,850.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586625 |
| Principal investigator 1 | ABBVIE INC. | $116.10 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503027 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368215 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368221 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368223 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368225 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368227 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368229 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368233 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368235 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368237 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368239 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.30 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368247 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368249 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368251 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $197.25 | 08/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368375 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320934 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796953 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796955 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $364.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378239 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $910.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378241 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,219.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,192.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378247 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,552.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378249 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42,993.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378251 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,274.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378257 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378259 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $364.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,181.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,730.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378265 |
| Principal investigator 1 | BioNTech SE | $40.00 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,433.25 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,914.44 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $951.44 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639478 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,392.63 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,860.95 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,950.00 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.00 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639486 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $203.13 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639492 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 07/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $168,179.20 | 07/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326748 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,269.33 | 07/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC | An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190301685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378233 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378235 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380182 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586484 |
| Principal investigator 1 | Incyte Corporation | $601.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586488 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586494 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586498 |
| Principal investigator 1 | Incyte Corporation | $325.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586501 |
| Principal investigator 1 | Incyte Corporation | $325.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586505 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586508 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586511 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586518 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586521 |
| Principal investigator 1 | Incyte Corporation | $601.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586525 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586530 |
| Principal investigator 1 | Incyte Corporation | $4,543.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586536 |
| Principal investigator 1 | Incyte Corporation | $325.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586541 |
| Principal investigator 1 | Incyte Corporation | $594.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586545 |
| Principal investigator 1 | Incyte Corporation | $379.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586548 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586603 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586607 |
| Principal investigator 1 | Incyte Corporation | $197.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586619 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202499274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378215 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $97.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175320907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321780 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324968 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325557 |
| Principal investigator 1 | Janssen Research & Development, LLC | $151.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325779 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651937 |
| Principal investigator 1 | ABBVIE INC. | $2,131.00 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498504 |
| Principal investigator 1 | ABBVIE INC. | $78.30 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498506 |
| Principal investigator 1 | ABBVIE INC. | $2,131.00 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498508 |
| Principal investigator 1 | ABBVIE INC. | $78.30 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498510 |
| Principal investigator 1 | ABBVIE INC. | $2,131.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378255 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,299.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378267 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,728.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $170.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380140 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380152 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 07/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380160 |
| Principal investigator 1 | Genentech, Inc. | $195.92 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651654 |
| Principal investigator 1 | Genentech, Inc. | $1,007.46 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651720 |
| Principal investigator 1 | Genentech, Inc. | $416.64 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651934 |
| Principal investigator 1 | Genentech, Inc. | $4,775.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651985 |
| Principal investigator 1 | Genentech, Inc. | $122.08 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652108 |
| Principal investigator 1 | Incyte Corporation | $3,129.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586346 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586352 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586391 |
| Principal investigator 1 | Incyte Corporation | $115.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. | No dispute reported | 06/30/2026 | 1240586657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,181.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378193 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223380202 |
| Principal investigator 1 | Genentech, Inc. | $847.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651851 |
| Principal investigator 1 | Genentech, Inc. | $1,565.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211652085 |
| Principal investigator 1 | Genentech, Inc. | $7,247.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652090 |
| Principal investigator 1 | Genentech, Inc. | $847.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211652166 |
| Principal investigator 1 | PFIZER INC. | $54.00 | 07/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228788053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328578 |
| Principal investigator 1 | Janssen Research & Development, LLC | $379.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329500 |
| Principal investigator 1 | BioNTech SE | $203.99 | 07/09/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018410 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784963 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784977 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,576.70 | 07/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796951 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327899 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328381 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328458 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328603 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328686 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328854 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329720 |
| Principal investigator 1 | BioNTech SE | $25.00 | 07/07/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018414 |
| Principal investigator 1 | BioNTech SE | $95.01 | 07/07/2025 | Non-covered Recipient Entity Florida Cancer Specialists | BNT326-01 | No dispute reported | 06/30/2026 | 1249018416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.00 | 07/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379608 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328321 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328399 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,275.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368193 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368195 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13.53 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.44 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368377 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.90 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368379 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11.90 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368381 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368385 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $131.50 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368387 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $88.50 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $354.00 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.30 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $131.50 | 07/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368399 |
| Principal investigator 1 | Genentech, Inc. | $830.00 | 07/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651923 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $845.00 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639470 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $650.00 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639472 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.00 | 06/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814635 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 06/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739057 |
| Principal investigator 1 | Janssen Research & Development, LLC | $63,962.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,159.80 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329600 |
| Principal investigator 1 | ABBVIE INC. | $3,436.43 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493319 |
| Principal investigator 1 | ABBVIE INC. | $3,561.30 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493331 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 06/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796905 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 06/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796907 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816872 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816874 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321435 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323934 |
| Principal investigator 1 | PFIZER INC. | $3,300.00 | 06/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228776590 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379178 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379182 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379290 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379294 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379316 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379320 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379326 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175327837 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328804 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,200.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,638.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,564.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378117 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378119 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378125 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378127 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,032.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,241.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378145 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,564.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378149 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378159 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,564.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,564.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378165 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378167 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $138.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378169 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $372.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378171 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378173 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378175 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378177 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378179 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378181 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378185 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,457.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,700.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13,000.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379386 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784883 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378163 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $71,860.00 | 06/18/2025 | Non-covered Recipient Entity Florida cancer specialist -DDU | A Phase 1b,2 Open-Label, Dose Escalation of ADG106 in Combination with Pembrolizumab Anti PD-1 Antibody and Expansion of ADG106 with or without Pembrolizumab in Patients with Advanced or Metastatic Solid and,or Hematological Malignancies | No dispute reported | 06/30/2026 | 1232932297 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,575.00 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796949 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 06/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376989 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,177.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376991 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,100.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376993 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,600.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376995 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,800.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376997 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223376999 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $23,697.00 | 06/16/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377001 |
| Principal investigator 1 | PFIZER INC. | $317.25 | 06/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228791566 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202490803 |
| Principal investigator 1 | ABBVIE INC. | $1,060.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202490805 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378123 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378155 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378157 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $488.32 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379260 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 06/09/2025 | Non-covered Recipient Entity FLORIDA CANCER CENTER & RESEARCH INSTITUTE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240535197 |
| Principal investigator 1 | Incyte Corporation | $23,000.00 | 06/09/2025 | Non-covered Recipient Entity FLORIDA CANCER CENTER & RESEARCH INSTITUTE | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | No dispute reported | 06/30/2026 | 1240535202 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $190.00 | 06/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226082006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 06/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321990 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325953 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,975.00 | 06/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175328974 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175329667 |
| Principal investigator 1 | ABBVIE INC. | $520.12 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202490207 |
| Principal investigator 1 | ABBVIE INC. | $4,994.00 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202490239 |
| Principal investigator 1 | ABBVIE INC. | $260.06 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202490241 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816868 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,800.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,100.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379318 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379336 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379348 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379350 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379356 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379364 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379368 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $115,386.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321019 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 06/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796903 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,700.00 | 06/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,235.81 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,526.69 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,362.94 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,235.81 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,995.50 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,093.63 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,567.31 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $886.44 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,048.50 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,235.81 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $802.75 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,629.88 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,146.63 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $568.75 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $345.31 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639462 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,943.50 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,567.31 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639466 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,048.50 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639468 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 05/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739059 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 05/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739061 |
| Principal investigator 1 | Incyte Corporation | $1,700.00 | 05/30/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534014 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 05/30/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534017 |
| Principal investigator 1 | ABBVIE INC. | $3,561.30 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486373 |
| Principal investigator 1 | ABBVIE INC. | $1,791.45 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486377 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $129.60 | 05/27/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814631 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651027 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 05/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379152 |
| Principal investigator 1 | PFIZER INC. | $3,300.00 | 05/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228773087 |
| Principal investigator 1 | Genentech, Inc. | $532.44 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650933 |
| Principal investigator 1 | Genentech, Inc. | $574.20 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651115 |
| Principal investigator 1 | Genentech, Inc. | $15.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651206 |
| Principal investigator 1 | Genentech, Inc. | $356.16 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651358 |
| Principal investigator 1 | Blueprint Medicines Corporation | $665.28 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378722 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378878 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379112 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379114 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379140 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379292 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379322 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,760.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379332 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379338 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379342 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379344 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379362 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379406 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379408 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534026 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/12/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534022 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 05/12/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534029 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 05/12/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534033 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 05/12/2025 | Non-covered Recipient Entity FCS - CATTLEMEN | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240534037 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,690.00 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,432.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $459.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378890 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223378998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379066 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $140.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $235.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $750.60 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $432.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379172 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,042.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $605.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $664.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,740.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379248 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379252 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379258 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379262 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379264 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379266 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379268 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379270 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379272 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379276 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379278 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379280 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379282 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379284 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379286 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,585.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379288 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379298 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379302 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379306 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379308 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379314 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,843.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379334 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379340 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379346 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379352 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379354 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379358 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379360 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,731.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379366 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379370 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379372 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379374 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379378 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,229.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379380 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379382 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,040.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,703.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379396 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,709.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379400 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,149.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223379402 |
| Principal investigator 1 | Genentech, Inc. | $172.48 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651541 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 05/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796945 |
| Principal investigator 1 | Blueprint Medicines Corporation | $3,131.25 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784850 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,743.53 | 05/07/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190305007 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,700.00 | 05/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796943 |
| Principal investigator 1 | ABBVIE INC. | $3,733.43 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480131 |
| Principal investigator 1 | ABBVIE INC. | $2,126.25 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480141 |
| Principal investigator 1 | ABBVIE INC. | $3,733.43 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480297 |
| Principal investigator 1 | ABBVIE INC. | $1,791.45 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480299 |
| Principal investigator 1 | ABBVIE INC. | $4,521.15 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480337 |
| Principal investigator 1 | ABBVIE INC. | $2,030.40 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480339 |
| Principal investigator 1 | ABBVIE INC. | $961.20 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480341 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 04/29/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,904.00 | 04/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325391 |
| Principal investigator 1 | Genentech, Inc. | $181.00 | 04/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650902 |
| Principal investigator 1 | Genentech, Inc. | $24,507.00 | 04/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650905 |
| Principal investigator 1 | Genentech, Inc. | $7,247.00 | 04/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651060 |
| Principal investigator 1 | Genentech, Inc. | $170.00 | 04/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175322284 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 04/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202478461 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 04/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 04/23/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 04/23/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.80 | 04/23/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220640477 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.40 | 04/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 04/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322997 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 04/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 04/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $913.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,299.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,732.00 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378189 |
| Principal investigator 1 | Genentech, Inc. | $2,391.67 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651528 |
| Principal investigator 1 | Genentech, Inc. | $44.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211651597 |
| Principal investigator 1 | Genentech, Inc. | $515.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651611 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969303 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.70 | 04/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814627 |
| Principal investigator 1 | Blueprint Medicines Corporation | $281.25 | 04/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784830 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,260.50 | 04/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796941 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814625 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 04/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226081998 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175320095 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175320864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175321627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175322074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $148.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175323762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175323797 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175324012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175324161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,555.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175324193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324417 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175325217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326405 |
| Principal investigator 1 | ModernaTX, Inc. | $790.00 | 04/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969299 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 04/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202468669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378133 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650880 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650987 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651002 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651161 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651172 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651261 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651367 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651423 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651555 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211651570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $134,992.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319982 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,092.15 | 04/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814623 |
| Principal investigator 1 | ModernaTX, Inc. | $187.50 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969295 |
| Principal investigator 1 | ModernaTX, Inc. | $1,942.50 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969301 |
| Principal investigator 1 | ABBVIE INC. | $1,156.95 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467404 |
| Principal investigator 1 | ABBVIE INC. | $1,156.95 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467408 |
| Principal investigator 1 | ABBVIE INC. | $4,521.15 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467422 |
| Principal investigator 1 | ABBVIE INC. | $2,715.53 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467425 |
| Principal investigator 1 | ABBVIE INC. | $4,521.15 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467558 |
| Principal investigator 1 | ABBVIE INC. | $2,226.15 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467562 |
| Principal investigator 1 | ABBVIE INC. | $3,733.43 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467565 |
| Principal investigator 1 | ABBVIE INC. | $2,226.15 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467569 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 03/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739063 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 03/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,404.00 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175318935 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $845.00 | 03/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | No dispute reported | 06/30/2026 | 1190305011 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,227.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,761.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $232.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368453 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368469 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368475 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368477 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368479 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368481 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368483 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368485 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368493 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $526.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17,814.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $21,610.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,530.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36,612.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368505 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368523 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368525 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368527 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368529 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368531 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,848.00 | 03/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368539 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 03/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784689 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796935 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796937 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $312.50 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796939 |
| Principal investigator 1 | Genentech, Inc. | $1,415.00 | 03/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650606 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220796901 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 03/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378505 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378509 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378539 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378545 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378547 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378563 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378571 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,638.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378591 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378599 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,638.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378692 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $926.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378720 |
| Principal investigator 1 | PFIZER INC. | $2,203.20 | 03/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228789623 |
| Principal investigator 1 | PFIZER INC. | $3,750.00 | 03/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228795198 |
| Principal investigator 1 | Celgene Corporation | $4,295.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute Llc | A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1222306813 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,550.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381946 |
| Principal investigator 1 | Genentech, Inc. | $181.00 | 03/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650302 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 03/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650495 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 03/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175320515 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175320564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,028.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175322483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175322802 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175325674 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175325927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 03/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $194.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378403 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378405 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.24 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,200.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378714 |
| Principal investigator 1 | Blueprint Medicines Corporation | $281.25 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784660 |
| Principal investigator 1 | ModernaTX, Inc. | $490.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969297 |
| Principal investigator 1 | Genentech, Inc. | $87,195.15 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 03/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796933 |
| Principal investigator 1 | AstraZeneca UK Limited | $690.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | ";A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administratered Orally in Combination with Intramuscular (IM) Fulvestrant to patients with Estrogen Receptor Positive (ER+) Advanced Metastatic Breast Cancer"; | No dispute reported | 06/30/2026 | 1185538791 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,777.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $49.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.24 | 03/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378690 |
| Principal investigator 1 | PFIZER INC. | $8,164.80 | 03/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228778761 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $625.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796931 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6.06 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368315 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $39.45 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $131.50 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368319 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $131.50 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368321 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368323 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.75 | 03/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,729.00 | 03/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175319503 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 03/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969291 |
| Principal investigator 1 | ABBVIE INC. | $3,370.95 | 02/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455226 |
| Principal investigator 1 | ABBVIE INC. | $3,370.95 | 02/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455229 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 02/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796929 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796915 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796917 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796921 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796923 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,131.00 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796925 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $156.25 | 02/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796927 |
| Principal investigator 1 | PFIZER INC. | $4,692.60 | 02/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228743050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381722 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.24 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,675.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $157.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,132.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381950 |
| Principal investigator 1 | PFIZER INC. | $4,200.00 | 02/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228754016 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,130.20 | 02/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814621 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240586337 |
| Principal investigator 1 | ModernaTX, Inc. | $190,000.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969305 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,546.70 | 02/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796913 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36,612.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,530.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368443 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,608.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368445 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,805.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368507 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368509 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17,814.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368511 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $526.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,966.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368515 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,160.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368519 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,848.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368521 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,227.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368535 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,424.00 | 02/19/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1471-079 | No dispute reported | 06/30/2026 | 1223368537 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 02/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452115 |
| Principal investigator 1 | Genentech, Inc. | $53,380.00 | 02/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650452 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 02/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650567 |
| Principal investigator 1 | Genentech, Inc. | $2,427.00 | 02/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650712 |
| Principal investigator 1 | Genentech, Inc. | $2,410.00 | 02/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 1a 1b of aCCR8 in Solid Tumors | No dispute reported | 06/30/2026 | 1211650859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,725.00 | 02/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175319495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $757.00 | 02/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175325712 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 02/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175326089 |
| Principal investigator 1 | Genentech, Inc. | $2,536.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650318 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph1 evaluating G6036 in pts with a KRAS Mutation | No dispute reported | 06/30/2026 | 1211650323 |
| Principal investigator 1 | Syndax Pharmaceuticals, Inc. | $3,890.00 | 02/05/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS - SOUTH | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION COHORT STUDY OF SNDX-5613 IN PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS, INCLUDING THOSE HARBORING AN MLL/KMT2A GENE REARRANGEMENT OR NUCLEOPHOSMIN 1 (NPM1) MUTATION | No dispute reported | 06/30/2026 | 1249050090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368099 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $127.20 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368103 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $127.20 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368117 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368119 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368123 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368125 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368127 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368133 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368145 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368149 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368155 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368157 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368159 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368163 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368165 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368167 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368169 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368171 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368173 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368175 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368177 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368179 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368181 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368185 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 02/04/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS1103-074 | No dispute reported | 06/30/2026 | 1223368191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $113,942.00 | 02/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175324388 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $90,937.00 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322261 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $490.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226084948 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institution Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226147759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $130.00 | 01/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Research Data Management Office | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220639432 |
| Principal investigator 1 | Eli Lilly and Company | $94,489.25 | 01/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | No dispute reported | 06/30/2026 | 1187889316 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 01/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer | No dispute reported | 06/30/2026 | 1233739067 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,429.50 | 01/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190305013 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 01/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442195 |
| Principal investigator 1 | ABBVIE INC. | $2,126.25 | 01/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202441403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 01/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816862 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14,781.12 | 01/27/2025 | Non-covered Recipient Entity Florida Cancer Specialists (sarasota) | A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1235997319 |
| Principal investigator 1 | Eli Lilly and Company | $1,605.19 | 01/27/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | No dispute reported | 06/30/2026 | 1187881532 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220796911 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 01/24/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab | No dispute reported | 06/30/2026 | 1220814619 |
| Principal investigator 1 | PFIZER INC. | $32,400.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228797841 |
| Principal investigator 1 | ABBVIE INC. | $116.10 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440748 |
| Principal investigator 1 | ABBVIE INC. | $675.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440751 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,500.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784680 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240586327 |
| Principal investigator 1 | PFIZER INC. | $6,600.00 | 01/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228798246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,257.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378387 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,418.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,459.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,418.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,257.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,125.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378399 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378613 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,122.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,122.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,304.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,922.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,304.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,413.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,304.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,693.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS1103-074 | No dispute reported | 06/30/2026 | 1223378631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,595.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381706 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,047.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,556.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,595.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,628.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,607.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,628.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,047.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,607.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,628.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,836.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,836.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,836.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,836.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,556.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,607.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,595.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,108.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,628.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,628.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,108.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,047.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,047.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381890 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,047.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,607.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,968.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,340.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,596.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,316.00 | 01/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS3939-077 | No dispute reported | 06/30/2026 | 1223381944 |
| Principal investigator 1 | ModernaTX, Inc. | $1,630.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969307 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,950.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | No dispute reported | 06/30/2026 | 1190303755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,011.90 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190304475 |
| Principal investigator 1 | ABBVIE INC. | $2,333.00 | 01/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202439667 |
| Principal investigator 1 | ABBVIE INC. | $78.30 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202438897 |
| Principal investigator 1 | Blueprint Medicines Corporation | $56.25 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235784676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,974.00 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175322082 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,600.00 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175323397 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175323595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,600.00 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175324499 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 01/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240586333 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $690.00 | 01/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226084952 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 01/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226084957 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,400.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1185538793 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,460.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816860 |
| Principal investigator 1 | Celgene Corporation | $102,221.08 | 01/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer | No dispute reported | 06/30/2026 | 1222305502 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $114,248.50 | 01/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1235993975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,607.00 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324471 |
| Principal investigator 1 | ModernaTX, Inc. | $1,490.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | No dispute reported | 06/30/2026 | 1252969293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368259 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368265 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368267 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368271 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368277 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368279 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368281 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.90 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368283 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.90 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368291 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $16.16 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.20 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368301 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368303 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.20 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368305 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.20 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12.12 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368309 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $468.70 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368311 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $132.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368313 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368325 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368327 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14.36 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368329 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368331 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.80 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368335 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368337 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368341 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368343 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.30 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368361 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368363 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368365 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.76 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368369 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368371 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.60 | 01/02/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute Sarasota Cattlemen | DS3939-077 | No dispute reported | 06/30/2026 | 1223368373 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.95 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377265 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377267 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377271 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377277 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377279 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377281 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377283 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6.60 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $237.25 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.55 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377291 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14.90 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.85 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377301 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377303 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377305 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377309 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 01/02/2025 | Non-covered Recipient Entity Regents Of The University Of Minnesota | DS7300-189 | No dispute reported | 06/30/2026 | 1223377311 |